Results 171 to 180 of about 318,817 (265)

Biochemical Studies and Production Optimization of β‐Glucosidase From Microcystis aeruginosa CACIAM 03 Using Organic Waste

Biotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Global warming and industrial pollutants pose significant threats to environmental sustainability. In response, enzymes have emerged as promising tools for mitigating pollution. Enzymatic hydrolysis is considered environmentally sustainable due to its biological nature.
Gustavo Marques Serra, Matheus Silva da Fonseca Diniz, Evonnildo Costa Gonçalves, Agenor Valadares Santos, Luciana Pereira Xavier   +4 more
wiley   +1 more source

Author Correction: CITED2 is a druggable epigenetic switch coupling neuronal maturation to regenerative decline. [PDF]

EMBO Mol Med
Müller F, McLachlan E, Costa AC, Qu J, Shrestha B, Wang Z, De Virgiliis F, Hutson TH, Zhou L, Kong G, Chadwick JS, La Montanara P, Yuan Z, Haberman N, Sousa MM, Palmisano I, Di Giovanni S.   +16 more
europepmc   +1 more source

Costa Rican Interpretations of Costa Rican Politics

Latin American Research Review, 1990
openaire   +1 more source

Integrated biorefinery for cellulosic ethanol and spherical nanolignin production from coconut waste

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract Green coconut waste was subjected to different fractionation methods to obtain integrated lignin nanoparticles and cellulosic ethanol. Pretreatment with gradual addition of dilute sulfuric acid provided a higher structural hemicellulose precursor yield (68.2%).
Ricardo Marchezan Farias de Mesquita, Júlia Caroline Dal Prá, Roselei Claudete Fontana, Sheila Montipó, Henrique Macedo Baudel, Eduardo Dieldold, Willian Daniel Hahn Schneider, Marli Camassola   +7 more
wiley   +1 more source

Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury

British Journal of Clinical Pharmacology, EarlyView.
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra, Luiza B. Negreiros, Amaury Pereira‐Acácio, Isadora G. Almeida, João P. M. Veloso‐Santos, Jarlene A. Lopes, Glória Costa‐Sarmento, Humberto Muzi‐Filho, Adalberto Vieyra   +8 more
wiley   +1 more source

Correction: Investigating the role of EGFR signalling in muscle dystrophies: implications for Duchenne muscular dystrophy. [PDF]

Cell Death Dis
Fernández-Simón E, Tejedera-Villafranca A, Fernández-Garabay X, Clark J, Monceau A, Villalobos E, Cox D, Azcón JR, Fernández-Costa JM, Diaz-Manera J.   +9 more
europepmc   +1 more source

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

British Journal of Clinical Pharmacology, EarlyView.
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask, Miina Lamminmäki, Olli Kampman, Mari Hämäläinen, Eeva Moilanen, Niko Seppälä, Anssi Solismaa   +6 more
wiley   +1 more source

Expanding the scope of practice for nurses: possibilities in five Latin American countries. [PDF]

Rev Lat Am Enfermagem
Moreno-Dias B, Angeli-Silva L, Prada-Sanabria CA, Silva TPC, Cassiani SHB, Puertas-Donoso EB.   +5 more
europepmc   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source